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Engineering of Saccharomyces cerevisiae 
for anthranilate and methyl anthranilate 
production
Joosu Kuivanen1,2, Matti Kannisto1* , Dominik Mojzita1, Heiko Rischer1, Mervi Toivari1 and Jussi Jäntti1
Abstract 
Background: Anthranilate is a platform chemical used by the industry in the synthesis of a broad range of high-value 
products, such as dyes, perfumes and pharmaceutical compounds. Currently anthranilate is produced via chemical 
synthesis from non-renewable resources. Biological synthesis would allow the use of renewable carbon sources and 
avoid accumulation of toxic by-products. Microorganisms produce anthranilate as an intermediate in the tryptophan 
biosynthetic pathway. Several prokaryotic microorganisms have been engineered to overproduce anthranilate but 
attempts to engineer eukaryotic microorganisms for anthranilate production are scarce.
Results: We subjected Saccharomyces cerevisiae, a widely used eukaryotic production host organism, to metabolic 
engineering for anthranilate production. A single gene knockout was sufficient to trigger anthranilate accumulation 
both in minimal and SCD media and the titer could be further improved by subsequent genomic alterations. The 
effects of the modifications on anthranilate production depended heavily on the growth medium used. By growing 
an engineered strain in SCD medium an anthranilate titer of 567.9 mg l−1 was obtained, which is the highest reported 
with an eukaryotic microorganism. Furthermore, the anthranilate biosynthetic pathway was extended by expres-
sion of anthranilic acid methyltransferase 1 from Medicago truncatula. When cultivated in YPD medium, this pathway 
extension enabled production of the grape flavor compound methyl anthranilate in S. cerevisiae at 414 mg l−1.
Conclusions: In this study we have engineered metabolism of S. cerevisiae for improved anthranilate production. The 
resulting strains may serve as a basis for development of efficient production host organisms for anthranilate-derived 
compounds. In order to demonstrate suitability of the engineered S. cerevisiae strains for production of such com-
pounds, we successfully extended the anthranilate biosynthesis pathway to synthesis of methyl anthranilate.
Keywords: Anthranilate, Methyl anthranilate, Saccharomyces cerevisiae, Metabolic engineering, Shikimate pathway
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Aromatic compounds varying from platform chemicals, 
such as polymer precursors, to high-value fine chemi-
cals including flavour, fragrance and pharmaceutical 
substances are widely used in different industries. These 
compounds are typically derived from benzene, toluene 
and xylene obtained from petroleum or natural gas, or 
from secondary metabolites extracted from plant tis-
sues. Recently, renewable production of aromatics and 
their derivatives using microbes has gained an increasing 
interest [1–4]. Among the compounds that are currently 
derived from petroleum, but could also be produced 
from renewables using industrial biotechnology, is the 
aromatic amine anthranilate (ANTH). ANTH is used for 
example as a precursor molecule in the production of 
dyes, fragrances and pharmaceuticals [5, 6]. Its derivative 
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plant-derived compound [7], constitutes a food flavour 
and cosmetic ingredient of significant demand.
ANTH is an intermediate in the microbial tryptophan 
(Trp) biosynthetic pathway and its production has been 
reported using engineered Escherichia coli [8], Pseu-
domonas putida [5] and Corynebacterium glutamicum 
[9] cells. In addition, production of a polymer precursor 
cis,cis-muconic acid (CCM) via ANTH in E. coli cells 
[10], and the flavor compound Me-ANTH in E. coli and 
C. glutamicum [9] have been reported.
Besides bacterial production hosts, the yeast Saccharo-
myces cerevisiae has raised interest as a chassis for aro-
matics production due to its robustness in bioprocess 
conditions [11] and the capability to express eukaryotic 
cytochrome P450 oxidases [12]–key enzymes in aromatic 
secondary metabolite pathways. S. cerevisiae has been 
engineered to convert ANTH to cinnamoyl, dihydrocin-
namoyl and benzoyl anthranilates, potential pharmaceu-
ticals [13]. These compounds were not however produced 
de novo, but ANTH feeding was required. Hitherto, 
ANTH production in S. cerevisiae had only been outlined 
in the patent literature [14]. Development and investiga-
tion of a S. cerevisiae platform for de novo ANTH pro-
duction could provide a platform for ANTH and its many 
derivatives, and give useful insight of the less frequently 
engineered Trp pathway in S. cerevisiae.
Similarly to bacterial hosts, aromatic compounds in S. 
cerevisiae are mainly synthesized through the shikimate 
(SA) pathway and the following aromatic amino acid 
pathways for phenylalanine (Phe), tyrosine (Tyr) and 
Trp (Fig. 1a). SA pathway begins with the aldol reaction 
of erythrose-4-phosphate (E4P) and phosphoenolpyru-
vate (PEP) forming 3-deoxy-D-arabino-heptulosonate-
7-phosphate (DAHP), catalysed by the DAHP synthases 
(EC 2.5.1.54) Aro3 and Aro4. In the next five reactions, 
DAHP is converted to 5-enolpyruvyl-shikimate-3-phos-
phate (EPSP) via 3-dehydroquinate (DHQ), 3-dehydro-
shikimate (DHS), SA and shikimate-3-phosphate (S3P). 
In bacteria, these reactions are catalysed by separate 
enzymes but in S. cerevisiae, the conversion is carried 
out by the action of the pentafunctional enzyme Aro1 
[15]. The last reaction from EPSP is catalysed by Aro2 
resulting in formation of chorismate (CHO)–a com-
mon precursor of the aromatic amino acids. After CHO 
formation, separate branches diverge for the biosynthe-
sis of Phe, Tyr and Trp. ANTH is the first intermediate 
in the Trp biosynthetic pathway and it is produced by 
Trp2/Trp3 complex in a reaction where an amide group 
Fig. 1 a A simplified representation of the metabolic pathways engineered in this study. The upregulated reactions are shown with green arrows 
and the eliminated reaction is shown with a crossed arrow. The reaction added to extend the pathway to Me-ANTH synthesis is shown with a blue 
arrow. b Modifications done to the strains generated in this study. c Workflow of the construction and characterization of the strains
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is transferred from glutamine (Gln) to CHO resulting in 
formation of ANTH and glutamate (Glu). Gln synthase 
encoded by GLN1 regenerates the consumed Gln from 
Glu and ammonia. The SA pathway is regulated by the 
allosteric inhibition of several enzymes, such as, Aro3, 
Aro4 [4] and Trp2. In addition, the flux through the SA 
pathway is limited by the availability of PEP, which is 
converted to pyruvate by the main pyruvate kinase of 
S. cerevisiae, encoded by CDC19 [16]. The availability 
of E4P from the pentose phosphate pathway (PPP) can 
also be considered a limiting factor because the carbon 
flux through E4P is low in S. cerevisiae [17].
In this study, the de novo production of ANTH is 
investigated in S. cerevisiae. Several upstream pathway 
genes were overexpressed by editing the chromosomal 
promoter regions of the target genes using a rapid 
CRISPR/Cas9 genome editing approach. In addition, 
the allosteric regulation of the SA pathway and the Trp 
branch was relieved with chromosomally integrated 
mutant enzymes. One of the ANTH overproduction 
strains was further engineered to produce the grape fla-
vour compound, Me-ANTH, by expressing anthranilic 
acid methyltransferase 1 (MtAAMT1) from Medicago 
truncatula. To the best of our knowledge, besides the 
patent literature [14] describing ANTH production in 
S. cerevisiae, this is the first report on engineering an 
eukaryotic strain for ANTH or Me-ANTH production.
Results
Construction and characterization of the strains
We used a prototroph S. cerevisiae strain CEN.PK113-
1A as a platform for the engineering of the ANTH-
producing S. cerevisiae strain. Gene deletions and the 
replacements of the native target gene promoters were 
generated using the two-plasmid CRISPR/Cas9 system 
described previously [18]. The plasmid expressing an 
sgRNA was transformed as PCR amplified fragments 
into a target S. cerevisiae strain that already maintained 
the Cas9 expression plasmid (see Additional file 1: Fig. 
S1), a method shown to enable a quick turnaround time 
in each engineering cycle [19]. The strains (Fig.  1b) 
were cultivated in microtiter plates using a cultivation 
robot [18], and both the optical density (OD) values 
together with the ANTH production were measured at 
the end of cultivation. Two different cultivation media 
were tested–the SCD medium containing 2% glucose 
and amino acids (except Phe and Tyr) and the Verduyn 
minimal medium containing 1% glucose and supple-
mented by Trp (due to the auxotrophy after the absence 
of Trp4 activity). The modified metabolic steps, gen-
erated strain and workflow are presented in Fig.  1a–c, 
respectively.
Triggering anthranilate accumulation by disruption 
of TRP4
The wild type strain did not produce ANTH in either 
media. When the TRP4 gene, encoding an ANTH phos-
phoribosyl transferase, was disrupted (strain 1), ANTH 
titers of 11.4 and 42.9  mg  l−1 were detected in SCD 
and minimal medium, respectively (Fig.  2a, c). A slight 
growth defect caused by TRP4-deletion was observed in 
SCD but not in minimal medium (Fig. 2b, d).
Relieving allosteric regulation of Aro4 and Trp2 
and overexpression of TRP3
To overcome feedback-inhibition of the DAHP synthases, 
we introduced the feedback insensitive variant ARO4K229L 
[20] of a DAHP synthase as a single-copy genomic inte-
gration into the trp4 locus without removing the native 
ARO4 (strain 2). This modification improved ANTH titer 
in SCD medium to 88.4 mg l−1 and in minimal medium 
to 104.5 mg l−1, but caused a small growth defect in SCD 
medium (Fig. 2b).
A feedback insensitive mutant TRP2S76L [21] was intro-
duced together with TRP3 overexpression cassette as 
single-copy genomic integrations into the ura3 and leu2 
loci, respectively, of the parental strain (to form strain 
3) and the ΔTRP4-ARO4K229L strain (to form strain 4) 
(Fig.  1b). Interestingly, the strain 3 without the deletion 
of TRP4 nor the expression of ARO4K229L produced simi-
lar titers of ANTH and had a more severe growth defect 
compared to strain 2. It is unlikely for the growth defects 
in the ANTH-producing strains described here to be 
due to toxicity of ANTH since it has been shown that 
yeast growth is not inhibited even at an ANTH concen-
tration of 2  g  l−1 [22]. When both feedback insensitive 
enzymes  Aro4K229L and  Trp2S76L were combined (strain 
4), the observed ANTH titers were doubled in both SCD 
(209.9  mg  l−1) and minimal (199.7  mg  l−1) media. Also 
the growth reduced significantly compared to the previ-
ous strains 1–3 (Fig. 2b, d).
Activation of ARO1, ARO2 and TKL1 by promoter 
replacements
Next, the SA pathway genes ARO1 and ARO2 were 
overexpressed by replacing the native promoters with 
known strong constitutive yeast promoters (Fig.  1b). 
The replacement was implemented through duplexed 
CRISPR genome edits into strain 4, forming strain 5. 
In SCD medium, the observed ANTH titer increased 
from 209.9 mg l−1 (strain 4) up to 367.9 mg l−1 while the 
growth remained at the same level (Fig.  2a, b). In con-
trast, a severe growth defect was observed in minimal 
medium resulting in low ANTH titer (Fig. 2c, d). How-
ever, when ANTH titer was normalized to OD (Fig.  2e, 
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f ), the production in minimal medium by the strain 5 
(35.0 mg l−1  OD−1) remained at a higher level than with 
the strains 1–3 (5.3–15.2 mg l−1  OD−1), but still lower as 
compared to the strain 4 (41.1 mg l−1  OD−1).
Overexpression of the transketolase TKL1 poten-
tially increasing flux towards E4P into strain 5 (result-
ing in strain 6) had a slightly negative effect on growth 
as compared to strain 5, but no significant effect on 
ANTH titer in SCD (Fig.  2a, b). However, OD normal-
ized ANTH production was increased from 45.2 mg  l−1 
 OD−1 to 55.2 mg l−1 OD−1 (Fig. 2e). In minimal medium, 
the growth defect resulting from ARO1 and ARO2 
overexpression in strain 5 was partially restored (Fig. 2d). 
In addition, the OD normalized ANTH production was 
higher (57.1 mg l−1 OD−1) compared to any of the previ-
ous strains 1–5 (5.3–41.1 mg l−1 OD−1) (Fig. 2f ).
Overexpression of the Gln synthase GLN1
To ensure sufficient Gln supply, we activated the native 
GLN1 expression by replacing its native promoter with 
a strong constitutive yeast promoter (Fig.  1b). As a 
result, when grown in SCD medium, we observed a sig-
nificant increase in the ANTH titer from 378.8 mg  l−1 
(strain 6) to 567.9 mg l−1 (strain 7) (Fig. 2a). At the same 
Fig. 2 ANTH titers at the end-point of the cultivations of the engineered strains 1–7 in SCD (a) and minimal medium (c). ODs of the cultivations in 
SCD (b) and minimal medium (d). The end-point ANTH titers divided by the end-point ODs of the engineered strains 1–7 in SCD (e) and minimal 
medium (f)
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time, only a slight reduction on growth was observed 
(Fig.  2b). However, the benefit from GLN1 activation 
was not observed when the strain was grown in mini-
mal medium (Fig. 2c, d, f ).
Down‑regulating the pyruvate kinase CDC19
We further attempted to increase the PEP flux 
towards ANTH by regulating the CDC19 expres-
sion in the strains 5, 6 and 7. Attempts to generate a 
glucose-growing null mutant failed, but we succeeded 
in replacing the native promoter with the PSP2 pro-
moter that has been shown to be a weak promoter [23]. 
In SCD medium, the OD normalized ANTH produc-
tion improved slightly in the modified strain 7 (from 
75.5 to 92.4  mg  l−1  OD−1) but not in the modified 
strains 5 (from 45.2 to 32.8 mg  l−1 OD−1) and 6 (from 
55.2 to 53.6  mg  l−1  OD−1) (Fig.  3a). A clear growth 
defect was observed in the modified strains 6 and 
7, but not in the strain 5. In contrast, only the strain 
5 showed an increase in the ANTH titer (from 35.0 to 
53.5 mg l−1 OD−1) in minimal medium (Fig. 3c). How-
ever, the growth of the strain 5 without the CDC19 
down-regulation (Fig.  3d) was very poor, which may 
affect this observation. Interestingly, the CDC19 down-
regulation restored the growth of strain 5 significantly. 
With the strains 6 and 7 in minimal medium, the down-
regulation affected the growth negatively.
Production of methyl anthranilate by expression 
of the MtAAMT1 gene
The strain 4 was selected a base strain for the produc-
tion of Me-ANTH due to its relatively fast growth and 
yet decent production of ANTH as compared to more 
engineered strains observed in minimal medium (Fig. 2c, 
d). The MtAAMT1 gene, encoding the M. truncatula 
anthranilic acid methyltransferase 1, was introduced as 
a single-copy genomic integration into the strain 4, and 
in the parental strain. The MtAAMT1 gene was expressed 
using the synthetic expression system (SES) [24] to 
achieve constitutive high production of the enzyme 
(see Additional file 1: Fig. S2). The identity of the prod-
ucts were confirmed by UPLC-MS analysis (see Addi-
tional file  1: Fig. S3). The modified strain 4 produced 
Me-ANTH to amounts similar to the amounts of ANTH 
produced by the original stain 4 (Fig.  4), indicating vir-
tually complete conversion of ANTH into Me-ANTH by 
the introduced methyltransferase. The titer of Me-ANTH 
exceeded 400 mg l−1 in YPD medium at day 5.
In order to verify the suitability of the strain 4 as a 
chassis and YPD as a medium for Me-ANTH produc-
tion, strains 4 and 7 were cultivated in YPD medium 
and strain 4, with or without MtAAMT1 expression, in 
SCD medium or minimal medium for 5 days. OD val-
ues were measured and ANTH and Me-ANTH titers 
determined from samples taken at the end point of 
the cultivation (Fig.  5). Strain 4 grew to a higher OD 
Fig. 3 ANTH titers at the end-point of the cultivations of the strains 5, 6 and 7 with and without CDC19 downregulation in SCD (a) and minimal 
medium (c). ODs of the cultivations in SCD (b) and minimal medium (d)
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and accumulated more ANTH than strain 7 in YPD 
medium (Fig. 5c), indicating that strain 4 is more suit-
able as a production host in this production medium. 
ANTH titers obtained with strain 4 and Me-ANTH 
titers obtained with strain 4 expressing MtAAMT1 
were much lower in SCD medium (Fig.  5b) and mini-
mal medium (Fig. 5a) than in YPD medium (Figs. 4, 5c). 
Furthermore, conversion of ANTH to Me-ANTH by 
strain 4 expressing MtAAMT1 was much less complete 
in SCD medium (Fig. 5b) and minimal medium (Fig. 5a) 
than in YPD medium (Fig. 4).
Fig. 4 ANTH and Me-ANTH titers in the cultivations of the parental strain and the strain 4, with and without the MtAAMT1 expression cassette. The 
cultivations were performed in YPD medium and the products analysed in the culture supernatants at day 2 (a) and day 5 (b)
Fig. 5 OD values and ANTH and Me-ANTH titers in the cultivations of strains 4, with or without MtAAMT1 expression, and 7. The strains were 
cultivated for 5 days in minimal medium (a), SCD medium (b) or YPD medium (c) and the products were measured in the culture supernatants
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Discussion
ANTH overproduction has been engineered in several 
prokaryotes but the suitability of eukaryotic species for 
ANTH production has received little attention. Only the 
patent application by Jäger et al. [14] suggest that ANTH 
production can be triggered in S. cerevisiae by disruption 
of TRP4. We attempted to engineer an efficient ANTH 
producing S. cerevisiae by first disrupting TRP4 from the 
genome of S. cerevisiae CEN.PK113-1A and then carry-
ing out extensive modifications to its genome to improve 
carbon flux towards ANTH biosynthesis. We introduced 
ARO4K229L, a gene for Aro4 mutant insensitive to feed-
back inhibition by Tyr [25], to the TRP4 locus. ARO4K229L 
has previously been successfully used in S. cerevisiae for 
example to improve the production of CCM [26], and 
double the product yield without affecting growth in a S. 
cerevisiae strain engineered to produce coumarate [27]. 
Here, the use of ARO4K229L improved ANTH titer in 
both media tested but did not affect growth in minimal 
medium and only very slightly in SCD medium.
We overexpressed TRP2S76L and TRP3 to funnel car-
bon towards ANTH production and reduce the flux to 
Phe and Tyr biosynthesis. This modification reduced OD 
slightly but did not affect ANTH titers significantly, thus 
increasing the OD normalized ANTH production. In the 
reaction catalyzed by Trp2 and Trp3 a pyruvate molecule 
is also formed. This pyruvate-forming reaction has been 
used to couple ANTH production to growth in E. coli 
by knocking out all other metabolic reactions producing 
pyruvate [28].
It has been shown that the overexpression of ARO1 
and ARO2 improves Tyr production in rich medium in 
a metabolically engineered S. cerevisiae strain [29]. This 
strain, which had also TKL1 expression upregulated, had 
also a slight growth defect [29]. In the experiments of 
Gold et al. [27], overexpression of ARO1 in a S. cerevisiae 
strain deleted for ARO10 knockout and expressing the 
ARO4K229L mutant improved production of the heterolo-
gous product coumarate without a significant effects on 
growth in the minimal medium. We show here that the 
activation of ARO1 and ARO2 improves ANTH produc-
tion and reduces growth of the engineered S. cerevisiae 
in minimal but not in SCD medium (strain 4 → 5). The 
p-hydroxyphenylpyruvate, an intermediate of Tyr bio-
synthesis, acts as an inhibitor to S. cerevisiae transketo-
lase [30]. Thus, the overexpression of ARO1 and ARO2, 
which increase flux towards Tyr biosynthesis, might have 
reduced transketolase activity. This would explain why 
overexpression of TKL1 (strain 5 → 6) restored growth 
slightly in minimal medium. As a growth defect was 
not seen in the amino acid containing SCD medium, it 
is likely that the reduction in growth in the minimal 
medium was due to reduced synthesis of some other 
metabolites, such as E4P. Furthermore, downregula-
tion of the gene for pyruvate kinase, CDC19, drastically 
improved the growth of the strain 5. Decrease in pyru-
vate kinase activity can be expected to result in the accu-
mulation of three carbon intermediates of glycolysis, 
including G3P which is converted to E4P and X5P in a 
reaction that consumes also one molecule of F6P. Thus, it 
seems likely that the overexpression of ARO1 and ARO2 
resulted in a growth defect through the depletion of the 
E4P pool, either directly by funnelling E4P towards SA 
pathway or by p-hydroxyphenylpyruvate-mediated tran-
sketolase inhibition. Deletion of glucose-6-phosphate 
dehydrogenase, ZWF1, and activation of transketolase, 
TKL1, have been shown to improve the product yield of 
the SA pathway derived CCM [26]. However, deletion 
of ZWF decreases the NADPH pool and if the product 
synthesis requires NADPH, the ZWF1 deletion may have 
a negative effect as shown previously [31]. For this rea-
son, we only activated the TKL1 but did not delete ZWF1 
(strain 5 → 6).
Expression of Gln synthase (glnA) has been shown to 
increase ANTH yield in a minimal medium of a meta-
bolically engineered E. coli strain [10]. Glu has been also 
shown to accumulate as a major side-product in an E. coli 
strain engineered for Trp production [32]. We upregu-
lated GLN1 expression in the engineered S. cerevisiae 
but did not observe improved ANTH titer in minimal 
medium while in SCD medium the ANTH titer improved 
significantly. It could be that either concentration of Gln 
is not limiting ANTH production or that the substrate of 
Gln synthase, Glu, is not present at sufficiently high con-
centration to affect ANTH production when strain 6 is 
cultivated in minimal medium.
Down-regulation of pyruvate kinase reaction has been 
considered as a potential approach to redirect the carbon 
flux towards aromatic amino acid biosynthesis. However, 
introduction of the mutation T21E in the CDC19 gene, 
which is known to reduce pyruvate kinase activity, has 
been shown not to increase flux of carbon to the aro-
matic amino acid biosynthesis pathway [27]. As pointed 
out by Suástegui et al. [31], this experiment was carried 
out in a ZWF1 knockout strain which might have affected 
the results. Since it has been shown that the CDC19 
null mutant cannot grow on glucose [33], we attempted 
to increase availability of PEP to the SA pathway in the 
strains 5–7 by downregulating pyruvate kinase activity. 
Growth was negatively affected in both SCD and minimal 
media for strains 6 and 7. In contrast, growth of strain 5 
was greatly improved in minimal medium. ANTH titer 
improved for strain 7 in SCD medium and for strain 5 
in minimal medium, while in other cases the ANTH 
titers either decreased or remained at the same level. 
Therefore, it seems that the effects of pyruvate kinase 
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down-regulation are highly dependent on the genetic 
background of the strain.
ANTH production has been successfully engineered 
in several prokaryotic microorganisms. For exam-
ple, P. putida has been engineered to produce a titer of 
0.25  g  l−1 of ANTH in a shake flask cultivation and a 
titer of 1.54 g  l−1 and a yield of 0.035  gANTH  gglucose−1 in 
a fed-batch cultivation in a minimal medium [5]. E. coli 
engineered for ANTH production produced a titer of 
0.75  g  l−1 and a yield of 0.20  gANTH  gglucose−1 in a batch 
cultivation in a minimal medium and a titer of 14  g  l−1 
and a yield of 0.20  gANTH  gglucose−1 in a fed-batch cultiva-
tion in rich medium [8]. E. coli and C. glutamicum have 
also been engineered for Me-ANTH production [9]. By 
fed-batch cultivating these strains in minimal medium, 
a Me-ANTH titer of 4.47  g  l−1 and a yield of 0.045 
 gMe-ANTH  gglucose−1 were obtained with E. coli and a titer 
of 5.74 g l−1 and a yield of 0.020  gMe-ANTH  gglucose−1 were 
obtained with C. glutamicum. Unlike prokaryotic host 
organisms, such as E. coli and P. putida which lack inter-
nal membranes, S. cerevisiae can express cytochrome 
P450 oxidases of eukaryotic origin [12], allowing pro-
duction of a broader range of ANTH derived metabo-
lites. Furthermore, ANTH production in S. cerevisiae is 
uncoupled from growth [14], allowing larger portion of 
the carbon source to be used in ANTH production. Cur-
rently the only reported attempt to engineer an eukaryote 
to produce ANTH can be found in the patent application 
by Jäger et al. who claim to have produced 320 mg l−1 of 
ANTH using an S. cerevisiae TRP4 knockout strain [14].
Conclusions
Here, we first knocked out the TRP4 gene from the 
genome of S. cerevisiae and then further engineered its 
metabolism for improved ANTH production. By carrying 
out batch cultivations with a strain optimized for ANTH 
production, we could obtain a titer of 199.7 mg  l−1 in a 
minimal medium and a titer of 567.9  mg  l−1 in SCD 
medium. Thus, we were able to nearly double the previ-
ously highest ANTH titer obtained with an eukaryotic 
microorganism. As these titers were obtained by cultivat-
ing the engineered S. cerevisiae strain on a microplate, 
drastically higher titers could be obtainable by controlled 
bioreactor cultivations e.g. in fed-batch mode. Further-
more, we show that these engineered S. cerevisiae strains 
are suitable for production of high value ANTH-derived 
compounds. By extending the pathway with a recently 
described anthranilic acid methyl transferase MtAAMT1 
from M. truncatula [34] the industrially valuable flavor 
compound Me-ANTH accumulated. While the ANTH 
titers still remain relatively low compared to the values 
obtained with prokaryotes, we foresee that the strains 
presented here can serve as a basis for the development 




All the plasmids were produced in E. coli TOP10 cells. 
The S. cerevisiae strains CEN.PK113-1A (MATα URA3 
HIS3 LEU2 TRP1 MAL2-8c SUC2) and CEN.PK113-17A 
(MATα ura3-52 HIS3 leu2-3,112 TRP1 MAL2-8c SUC2) 
were used as parental strains. Detailed description of 
the engineered S. cerevisiae strains used in this study is 
shown in Fig.  1b. The strains used in the experiments 
where the Me-ANTH production was tested (shown in 
Figs. 4, 5) were constructed as follows. The parental strain 
and the strain 4 were transformed with the MtAAMT1 
expression cassette released from the pHIS3in-kanMX_
SES-MtAAMT1 plasmid by NotI. The corresponding 
negative control strains were also constructed by trans-
formations of the kanMX selection marker cassette 
released from the plasmid pHIS3in-kanMX by NotI. The 
transformed strains were selected for growth in presence 
of G-418 (YPD agar with 200 mg l−1 of G-418), and tested 
for the correct genomic integrations into the HIS3 locus 
by qPCR (primers listed in Table 1).
Media and culture conditions
Luria Bertani Broth culture medium supplemented with 
100 µg ml−1 of ampicillin or 25 µg ml−1 of chlorampheni-
col and culture conditions of 37  °C and 250  rpm were 
used with E. coli. YPD medium (10  g  l−1 yeast extract, 
20 g l−1 peptone and 20 g l−1 D-glucose) with 200 µg ml−1 
of G418 was used for S. cerevisiae pre-cultures. For selec-
tion of transformants with TRP2S76L and TRP3 integra-
tion cassettes, SCD-Ura-Leu (uracil and leucine deficient 
synthetic complete media supplemented with 20 g D-glu-
cose  l−1) plates were used for uracil auxotrophic selec-
tion. All the S. cerevisiae cultivations were carried out at 
30  °C and small scale liquid cultivations were shaken at 
250 rpm.
The characterization of the engineered S. cerevisiae 
strains was carried out in 96-well plates using a Beckman 
Coulter screening and cultivation robot as described pre-
viously [18]. Briefly, two sequential 24-h pre-cultivation 
steps in YPD and SCD-Phe-Tyr (Phe and Tyr deficient 
synthetic complete media supplemented with 20  g  l−1 
D-glucose) or defined minimal medium [35] (supple-
mented with 0.4 mM Trp and 10 g l−1 D-glucose), respec-
tively, were carried out (Fig.  1c). The final cultivations 
were done in SCD-Phe-Tyr medium for 45  h and mini-
mal medium for 72  h. The cultivation volume of 150  µl 
was used in each step and inoculation volume of 10 µl in 
each transfer. Cultivations were monitored by measuring 
OD at 595 nm in 2-h intervals. The strains were further 
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characterized by cultivating 5  days in 50  ml of SCD-
Phe-Tyr medium or minimal medium (strain 4) or YPD 
medium (strains 4 and 7). OD was measured and UPLC-
MS samples taken at the end point of the cultivation.
The production of Me-ANTH was performed in 50 ml 
of SCD-Phe-Tyr medium, minimal medium or YPD 
medium. The strains were cultivated in duplicate (YPD 
medium) or triplicate (SCD-Phe-Tyr medium and mini-
mal medium) liquid cultures in 250 ml Erlenmeyer flasks 
for 5 days at 30 °C with a shaking of 220 rpm. The culture 
supernatant samples were collected by centrifugation in 
day 2 and day 5, and subjected to the UPLC-MS analysis.
Unless stated otherwise, all cultivations were carried 
out in triplicates. Figures 2, 3, 4, 5 represent average val-
ues from measurements taken from these cultivations 
and error bars represent standard deviations.
Plasmids and DNA construction
Expression cassette for the allosterically insensitive 
DAHP synthase ARO4K229L was constructed by PCR 
amplifying the ARO4K229L open reading frame (ORF) 
in two parts from S. cerevisiae genomic DNA with the 
primers oJKLiF-016/-017 and oJKLiF-018/-019 (Table 1). 
The primers oJKLiF-017 and -018 introduced the K229L 
mutation and contained the homology arms for mutual 
recombination. Primers oJKLiF-016 and -019 contained 
the homology arms for the EcoRI and BamHI digested 
yeast expression plasmid derived from pYX212 [36]. 
These two PCR fragments were combined and cloned 
into the digested expression plasmid backbone using the 
yeast homologous recombination. As a result, ARO4K229L 
was in the yeast expression plasmid under TPI1p. For 
genomic integrations, ARO4K229 expression cassette was 
PCR amplified with the primers oJKLiF-084/-085, intro-
ducing homology arms for the genomic TRP4 integra-
tion, respectively. Similar to ARO4K229L, allosterically 
insensitive TRP2S76L mutant was PCR amplified in two 
fragments with the primers oJKLiF-133/-134 and oJK-
LiF-135/-136. The resulting fragments were fused with 
an additional PCR using primers oJKLiF-133/-136 and 
transferred to Yeast MoClo entry vector [23]. TRP3 gene 
was PCR amplified with the primers oJKLiF-137/-138 
and transferred to MoClo entry vector. Yeast MoClo 
method was used to construct integration cassettes for 
Table 1 Primers used in the construction of the strains
Primer Sequence (5′ → 3′)
oJKLiF-016 TGC TTA AAT CTA TAA CTA CAA AAA ACA CAT ACA GGA ATT CCA CCA TGA GTG AAT CTC CAA TGTT 
oJKLiF-017 CGT TAC CCT TAG TAG TGG TGA TAG CAG CAA CAC CAT GCA AAG TAA CAC CCA TGA AAT GGT G
oJKLiF-018 AGC CGC TGC TCA TTC TCA CCA TTT CAT GGG TGT TAC TTT GCA TGG TGT TGC TGC TAT CAC 
oJKLiF-019 CTT ATT CAG TTA GCT AGC TGA GCT CGA CTC TAG AGG ATC CCT ATT TCT TGT TAA CTT CTC 
oJKLiF-084 ACT GAC AAC TAA GTG AAT TTA AAC TGC AAT AAT CAC AAG AAA ACT TAG TAT TCC CTT ATC CTA GTG TTT AAA GAT TAC GG
oJKLiF-085 TTC AGC TTA GTA CAA ATA AAA CGT CTC TAT CTA GTT TAA GTA TAA CAT ATG AAA TAA TGT CGA ATT GGA GCT AGA CAA AG
oJKLiF-133 GCA TCG TCT CAT CGG TCT CAT ATG ACC GCT TCC ATC AAAAT 
oJKLiF-134 GTG GCG AGA TAC CTA TGA ATA AAT AAC GAT CTA ATT CATTA 
oJKLiF-135 TAT TCA TAG GTA TCT CGC CAC 
oJKLiF-136 ATG CCG TCT CAG GTC TCA GGA TTT AAG CTG ATC CTA CGA TAT 
oJKLiF-137 GCA TCG TCT CAT CGG TCT CAT ATG TCT GTG CAC GCT GCAAC 
oJKLiF-138 ATG CCG TCT CAG GTC TCA GGA TTT ATT CGC ATA ATT CAT GAA TG
oNNF-003 GAC ACC CGA CAG ATC AAG GC
oNNF-004 GCA CGG TTA TCC ACA GAA TC
8BS_mCh_GA_F GAT ACT AAC GCC GCC ATC CAG TGT CGG CGC GCC GAA TTA ACC CTC ACT AAAGG 
8BS_mCh_GA_R GAT TCC ATT GTA GAT ATT TAA TTA TGT GTG TTT ATT CGA AAC TAA GTT CTTG 
sTF_noPacI_GA_F CGA ATA AAC ACA CAT AAT TAA ATA TCT ACA ATG GAA TCT ACT CCT ACT AAG CAA AAAGC 
sTF_noPacI_GA_R GCT GCA GCT TTA AAT AAT CGG TGT CAG ATA TCA GGA TCA ATG GCG TCG GACA 
MtAAMT1_GA_F CTG CTT ATC AAC ACA CAA ACA CTT AAT TAA AAT GGA AGT TGC TCA AGT TTT ACC AATG 
MtAAMT1_GA_R CAT AAA TCA TAA GAA ATT CGG ATC CTC AAG CTT TTC TAG TCA TCA TTA AAG TCA AAT TAG 
MtAAMT1_qPCR_F GAA ATG GAA ACT GAA ATG GGTC 
MtAAMT1_qPCR_R CGT TAG ATG GTG ATG TAG AAGTC 
Sc_HIS3_qPCR_F TCG CAA GTG ATT AAC GTC CA
Sc_HIS3_qPCR_R CGC AAA TCC TGA TCC AAA CCT 
kanMX_qPCR_F TAT TGT TGA TGC GCT GGC AG
kanMX_qPCR_R TAT TCA TTC GTG ATT GCG CC
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TRP2S76L and TRP3. TRP2S76L cassette composed of the 
following building blocks: pYTK-002, -009, -051, -067, 
-074, -087, -089 and -093 resulting in LEU2 targeted 
integration cassette with URA3 selection marker and 
TRP2S76L expressed under TDH3p. The corresponding 
composition of the TRP3 cassette was: pYTK-003, -011, 
-052, -068, -075, -086, -089 and -092 resulting in URA3 
targeted integration cassette with LEU2 selection marker 
and TRP3 expressed under PGK1p. Promoter switches 
for the genes ARO1, ARO2, GLN1 and CDC19 were car-
ried out by using PCR amplified promoters flanked with 
homology arms as a donor DNA.
The expression cassette for the MtAAMT1 was con-
structed in the S. cerevisiae integrative plasmid targeting 
the HIS3 locus. The plasmid was based on previously con-
structed pHIS3in-SpHIS5 and pGRE3in-kanMX plasmids 
[37]. The kanMX selection marker from the pGRE3in-
kanMX was cloned in place of the SpHIS5 marker in the 
pHIS3in-SpHIS5 between AscI and BglII restrictions sites 
to make the pHIS3in-kanMX plasmid. This plasmid was 
further modified by inserting DNA parts from plasmid 
pLEU2in-SES-A* [24]. Two DNA fragments from the 
pLEU2in-SES-A* were obtained by PCR with primers 
8BS_mCh_GA_F and 8BS_mCh_GA_R and sTF_noPacI_
GA_F and sTF_noPacI_GA_R (Table  1), and these two 
fragment were assembled between AscI and EcoRI of the 
pHIS3in-kanMX by the Gibson assembly method (NEB). 
The resulting plasmid pHIS3in-kanMX_SES-A* was used 
for the final construction step, where the PCR product 
containing the S. cerevisiae codon-optimized MtAAMT1 
coding region (MtAAMT1 from Medicago truncatula; 
NCBI Reference Sequence: XP_003604791.1; codon opti-
mized and ordered as a synthetic gene (Genescript, USA) 
with suitable DNA flanks) was inserted between PacI and 
BamHI sites to form pHIS3in-kanMX_SES-MtAAMT1. 
The MtAAMT1 coding sequence was amplified by PCR 
using primers MtAAMT1_GA_F and MtAAMT1_GA_R 
(Table 1). The final expression cassette was confirmed by 
sequencing.
S. cerevisiae genome editing
For the CRISPR/Cas9 mediated genomic integrations, 
an approach based on a two plasmid system–Cas9 and 
single-guide RNA (sgRNA) expressed from separate 
plasmids–was used similar as described previously [18]. 
The Cas9 expression vector was constructed from Yeast 
MoClo parts pYTK-002, -013, -036, -051, -067, -077, -081 
and -083 resulting in a CEN/ARS plasmid with KanR 
selection marker and Cas9 expressed under TEF1p. All 
the sgRNA plasmids were based on a backbone which 
was constructed from the Yeast MoClo parts pYTK-
002, -013, -051, -067, -078, -082 and -083 resulting in a 
2µ plasmid with NatR selection marker. This backbone 
was PCR amplified with the primers oNNF-003/-004 
and was co-transformed into S. cerevisiae together with 
a PCR amplified DNA fragment containing an expres-
sion cassette for sgRNAs (expressed between pSNR52 
and tSUP4). The workflow of the CRISPR/Cas9 method 
is described in the Additional file 1: Fig. S1  and the oligos 
for construction of each sgRNA expression cassettes are 
listed in Table  1. All S. cerevisiae transformations were 
carried out by using the Gietz transformation method 
[38]. About 0.5–1  µg of sgRNA plasmid backbone and 
expression cassette and 1–5 µg of donor DNA was used 
in the transformations.
Chemical analyses
The yeast liquid cultures were centrifuged and ANTH / 
Me-ANTH titers were analyzed from the supernatants. 
UPLC was carried out using ACQUITY UPLC BEH HSS 
T3 Column, 1.8 µm, 2.1 mm X 100 mm (Waters) kept at 
45 °C. An injection volume of 2 µl was used. Flow rate of 
the mobile phase A (0.1% of formic acid in water) and B 
(0.1% of formic acid in methanol) was 0.4 ml min−1. Fol-
lowing gradient program was used: 5.0% of B at 0.0 min, 
60.9% of B at 4.3 min, 97.1% of B at 5.6 min, and 95.0% 
of B at 6.0  min. Equilibrium time of 2.0  min was used 
between runs.
Mass spectrometry was carried out using electrospray 
ionization (ESI) in positive polarity. The capillary volt-
age was 3.0  kV, cone voltage 30  kV, source temperature 
150  ºC and desolvation temperature 500  ºC. The cone 
and desolvation gas flow were set at 150 l h−1 (nitrogen) 
and 1000  l h−1 (nitrogen), respectively, collision gas was 
0.15 ml min−1. The analysis was performed with ANTH 
and Me-ANTH as analytical standards for the identifica-
tion and quantification of the products.
Supplementary Information
The online version contains supplementary material available at https ://doi.
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Additional file 1: Fig. S1 The workflow of the CRISPR/Cas9 method used 
in the strain construction. The S. cerevisiae strain was first transformed 
with the Cas9 expression vector and then with the linear fragments of the 
sgRNA expression cassette, the sgRNA expression plasmid backbone and 
the donor DNA. The sgRNA expression cassettes were produced by two 
PCR reactions. The first PCR produces the target specific 20 nucleotide 
sequence and results in two fragments. The second PCR then amplifies 
the whole cassette fusing these fragments together. The sgRNA expres-
sion plasmid is formed by homologous recombination in vivo from the 
sgRNA expression cassette and the plasmid backbone. After each round 
of genomic integrations, the sgRNA expression plasmid is dropped from 
the cells by growing on non-selective medium which allows new round 
of modification to be carried out. Fig. S2 The expression cassette used for 
the MtAAMT1 expression in the S. cerevisiae strain engineered for ANTH 
production (strain 4). Fig. S3 Example of UPLC-MS analysis of ANTH and 
Me-ANTH. The top panel represents the base peak intensity (BPI) chroma-
tograms of analytical standards, ANTH and Me-ANTH as detected by mass 
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spectrometry. The lower panels show the same analysis of production of 
the compounds by the strain 4 and the strain 4 modified by the expres-
sion cassette for MtAAMT1. 
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